Jamp-Finasteride · DIN 02357224 · 5 mg · tablet
Limited Use, Reason for Use code 384, 385 requiredDormant since August 3, 2026 · checked November 18, 2026 · What does dormant mean?
StatusLimited Use, Reason for Use code 384, 385 required
Write on scriptone applicable Reason for Use code, 384 or 385 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 384, 385
Reason for Use code 384
For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia.
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 385
For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker.
Coverage limit:
* Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains:
1. feeling of incomplete emptying of the bladder after voiding
2. needing to urinate again less than 2 hours after previous void
3. stopping and starting urine several times while voiding
4. difficulty postponing urination
5. weak urinary stream
6. pushing or straining to begin voiding
7. the need to get up to void at least 3 times in the night.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp-Finasteride · DIN 02357224
Manufacturer: Jamp Pharma Corporation; listing date 2011-03-15
Health Canada: Dormant since 2026-08-03 · brand JAMP-FINASTERIDE · ATC G04CB01 FINASTERIDE · form Tablet · route Oral · ingredients FINASTERIDE 5 MG · company Jamp pharma corporation · schedule Prescription
Jamp-Finasteride: Formulary list price $0.35 per unit (the source does not state the unit; exact figure $0.3506). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02357224)
Source record
DIN 02357224: Jamp-Finasteride
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 920000067; group id 915; item number 2189; lccId 00155; manufacturer id JPC
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3506; ministry $0.3506
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02357224
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84235
Interchangeable products
Apo-Finasteride · DIN 02365383 · $0.3506
Auro-Finasteride · DIN 02405814 · $0.3506
Finasteride · DIN 02445077 · $0.3506
Finasteride · DIN 02447541 · $0.3506
Finasteride Tablets USP · DIN 02355043 · $0.3506
M-Finasteride · DIN 02522489 · $0.3506
Mint-Finasteride · DIN 02389878 · $0.3506
NRA-Finasteride · DIN 02535637 · $0.3506
Novo-Finasteride · DIN 02348500 · $0.3506
PMS-Finasteride · DIN 02310112 · $0.3506
Proscar · DIN 02010909 · $0.3506
Ratio-Finasteride · DIN 02306905 · $0.3506
Riva-Finasteride · DIN 02455013 · $0.3506
Sandoz Finasteride · DIN 02322579 · $0.3506
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Dormant since August 3, 2026 — choose a marketed DIN from the same-category list.